PETER H LAW, M.D.
Osteopathic Medicine at Poplar Ave, Memphis, TN

7341719, Mar 11, 2008

Jan 9, 1998

09/005034

Peter K. Law - Memphis TN, US

A01N 65/00, C12N 5/08

424 937, 424 931, 424 9321, 435366

Compositions and methods of treating mammalian diseases using myoblasts, and/or their physical, genetic, chemical derivatives. Myogenic cells that are normal, or genetically or phenotypically altered are cultured and transplanted into malfunctioning and/or degenerative tissues or organs to alleviate conditions that are hereditary, degenerative, debilitating, undesirable, and/or fatal. Treatment of these conditions is not limited to the usage of mechanical, electrical or physical properties of these myogenic cells, but includes the usage of biochemicals secreted/released by the latter. The present invention discloses the use of normal myoblasts to deliver the complete normal genome to effect genetic repair, or to augment the size, or the function of tissues or organs. Certain conditions may be better served with genetically altered myogenic cells derived from gene transduction, whereas others may be better served with cytoclimes converter cells. Endogenous biochemical(s) are used to control cell fusion of myoblasts among themselves or with other cell types.

2002003, Mar 14, 2002

May 31, 2001

09/867519

Peter Law - Memphis TN, US

A61K048/00, A01N063/00, C12N005/00, C12N005/02, C12N005/06, C12N005/12

424/093210, 424/093200, 435/346000, 435/325000

Compositions and methods of treating mammalian diseases using myoblasts, and/or their physical, genetic, chemical derivatives. Myogenic cells that are normal, or genetically or phenotypically altered are cultured and transplanted into malfunctioning and/or degenerative tissues or organs to alleviate conditions that are hereditary, degenerative, debilitating, undesirable, and/or fatal. Treatment of these conditions is not limited to the usage of mechanical, electrical or physical properties of these myogenic cells, but includes the usage of biochemicals secreted/released by the latter. The present invention discloses the use of normal myoblasts to deliver the complete normal genome to effect genetic repair, or to augment the size, or the function of tissues or organs. Certain conditions may be better served with genetically altered myogenic cells derived from gene transduction, whereas others may be better served with cytoclimes converter cells. Endogenous biochemical(s) are used to control cell fusion of myoblasts among themselves or with other cell types. An automated cell processor within a cell bank which enables the manufacture, at a single run, of unprecedented large quantities (greater than 100 billion) of normal or genotypically or phenotypically altered myogenic cells is also disclosed.

6261832, Jul 17, 2001

Jan 9, 1998

9/005035

Peter K. Law - Memphis TN

C12M 300

4352865

Compositions and methods of treating mammalian diseases using myoblasts, and/or their physical, genetic, chemical derivatives. Myogenic cells that are normal, or genetically or phenotypically altered are cultured and transplanted into malfunctioning and/or degenerative tissues or organs to alleviate conditions that are hereditary, degenerative, debilitating, undesirable, and/or fatal. Treatment of these conditions is not limited to the usage of mechanical, electrical or physical properties of these myogenic cells, but includes the usage of biochemicals secreted/released by the latter. The present invention discloses the use of normal myoblasts to deliver the complete normal genome to effect genetic repair, or to augment the size, or the function of tissues or organs. Certain conditions may be better served with genetically altered myogenic cells derived from gene transduction, whereas others may be better served with cytoclimes converter cells. Endogenous biochemical(s) are used to control cell fusion of myoblasts among themselves or with other cell types.

2003023, Dec 18, 2003

Apr 1, 2003

10/403520

Peter Law - Germantown TN, US

C12N005/08

435/366000

Myoblast cells obtained by culturing, particularly from satellite cells or other progenitor cells, are transplanted into tissue such as diseased heart tissue to form healthy repair tissue and reverse disease. This technique can be carried out in various ways and preferably includes a cellular integration factor to assist cellular survival, integration and longevity into the treated organ. Angiogenesis factors such as vascular endothelial growth factor are particularly preferred and may be transgenically expressed by the transplanted cell. Other factors that may be used to augment the procedure include migratory and scaffolding molecules. The methods and materials are particularly useful in combination with an automated cell processor and an automated catheter delivery system. The materials and methods for their use may be applied to the prophylaxis and therapy of damaged hearts, using cells originally obtained from the patient, another human, or another animal.

5130141, Jul 14, 1992

May 30, 1991

7/708801

Peter K. Law - Memphis TN
Tena G. Goodwin - Memphis TN

A61K 3534, C12N 500

424548

Compositions for and methods of treating muscle weakness and degeneration are described. Such compositions include myogenic cells which are administered by the described methods to one or more affected muscles.

7166279, Jan 23, 2007

Nov 8, 2001

09/986344

Peter K. Law - Memphis TN, US

A61K 48/00, C12N 5/10

424 9321, 435366, 424 932

An analgesic benefit is realized by continuously supplying a peptide in vivo that activates an opioid receptor or that interferes with the binding of substance P to its receptors. The long-term, continuous provision of such a peptide can be accomplished by (a) transducing myogenic cells with DNA expressing the peptide and (b) administering the transduced myogenic cells to a patient, such that the cells continuously produce the peptide.